ADP	Adenosine diphosphate
AML	Acute myeloid leukaemia
ASCO	American Society for Clinical Oncology
BICR	Blinded independent central review
ctDNA	Circulating tumour DNA
CPS + EG	Clinical and pathological stage plus oestrogen receptor and nuclear grade
CRISPR	Clustered regularly interspaced short palindromic repeats/associated proteins
CR	Complete response
CI	Confidence interval
dMMR	DNA mismatch repair deficiency
FDA	Food and Drug Administration
gBRCAm	Germline BRCA mutation
GIS	Genomics instability score
HR	Hazard ratio
HBOC	Hereditary Breast and Ovarian Cancer
HGEOC	High-grade epithelial ovarian cancer
HGSOC	High-grade serous ovarian carcinoma
HRR	Homologous recombination repair
HRRm	Homologous recombination repair gene mutations
HRD	Homologous repair deficiency
ibPFS	Imaging-based progression-free survival
ITT	Intention to treat
iDFS	Invasive disease-free survival
LPV	Likely pathogenic variant
LOH	Loss of heterozygosity
MSI-H	Microsatellite instability high
mCRPC	Metastatic castrate-resistant prostate cancer
MDS	Myelodysplastic syndrome
NGS	Next-generation sequencing
NHEJ	Non-homologous end joining
NHAs	Novel hormonal agents
NR	Not reached
ORR	Overall response rate
OS	Overall survival
PR	Partial response
PV	Pathogenic variant
PTIP	Pax2 transactivation domain-interacting protein
PAR	Poly ADP-ribose
PARylation	Poly ADP-ribosylation
PARG	Poly ADP-ribose glycohydrolase
PARP	Poly adenosine diphosphate ribose polymerase
PARPi	Poly adenosine diphosphate ribose polymerase inhibitor
pMMR	Proficient DNA mismatch repair
PD-1	Programmed cell death protein 1
PD-L1	Programmed death-ligand 1
PFS	Progression-free survival
rPFS	Radiologic progression-free survival
TNBC	Triple-negative breast cancer
tBRCAm	Tumour BRCA mutation
TME	Tumour microenvironment
53BP1	TP53-binding protein 1
Vd	Volume of distribution
WT	Wild type